Captrust Financial Advisors Sells 4,901 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Captrust Financial Advisors trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,714 shares of the medical equipment provider's stock after selling 4,901 shares during the quarter. Captrust Financial Advisors' holdings in Zimmer Biomet were worth $3,639,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ZBH. Cetera Investment Advisers increased its stake in Zimmer Biomet by 9.2% in the first quarter. Cetera Investment Advisers now owns 64,491 shares of the medical equipment provider's stock valued at $8,512,000 after purchasing an additional 5,454 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Zimmer Biomet by 30.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 875 shares of the medical equipment provider's stock valued at $105,000 after purchasing an additional 202 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Zimmer Biomet by 81.6% during the second quarter. GAMMA Investing LLC now owns 986 shares of the medical equipment provider's stock worth $107,000 after buying an additional 443 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of Zimmer Biomet in the second quarter valued at approximately $257,000. Finally, CWM LLC boosted its position in Zimmer Biomet by 4.3% during the second quarter. CWM LLC now owns 6,485 shares of the medical equipment provider's stock worth $704,000 after acquiring an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

NYSE:ZBH traded down $0.13 on Wednesday, reaching $110.61. The stock had a trading volume of 1,438,157 shares, compared to its average volume of 1,493,587. The company has a market capitalization of $22.02 billion, a P/E ratio of 21.05, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. The stock has a fifty day moving average price of $107.41 and a 200-day moving average price of $109.15. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the company earned $1.65 EPS. Zimmer Biomet's revenue for the quarter was up 4.1% on a year-over-year basis. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZBH. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Robert W. Baird dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research report on Thursday, August 8th. TD Cowen decreased their price target on Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating for the company in a research note on Friday, September 6th. Wolfe Research began coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a "peer perform" rating for the company. Finally, Raymond James lowered their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research report on Monday, October 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.